Showing 4881-4890 of 6036 results for "".
- Heru Series A Funding Accelerates Cloud and AI-Enabled Wearable Vision Diagnosis and Therapyhttps://modernod.com/news/heru-series-a-funding-accelerates-cloud-and-ai-enabled-wearable-vision-diagnosis-and-therapy/2479231/Heru, developer of wearable AI-powered vision diagnostics and augmentation software, closed its Series A financing of $30 million to advance the company’s eye diagnostic and vision correction technology platform. Originating as a spinout from Bascom Palmer Eye Institute, the Series A follo
- MedOne Surgical Receives FDA Clearance for its MicroDose Injectorhttps://modernod.com/news/medone-surgical-receives-fda-clearance-for-its-microdose-injector/2479227/MedOne Surgical announced the FDA 510(k) clearance of its MicroDose Injector device for low volume ophthalmic injections into the subretinal space. The pneumatically driven syringe system allows the surgeon to utilize a pneumatic air source, such as a vitrectomy system, to deliver a low volume in
- Bio-Techne and Narayana Nethralaya Collaborate On the Use of Ella for Ophthalmic Disorder Diagnostic Applicationshttps://modernod.com/news/bio-techne-and-narayana-nethralaya-collaborate-on-the-use-of-ella-for-ophthalmic-disorder-diagnostic-applications/2479224/Bio-Techne announced a collaboration with Narayana Nethralaya to develop a diagnostic solution for ophthalmology disorders on its ProteinSimple branded, multiplexing immunoassay instrument, Ella. The Ella platform, which is currently sold for research use only, allows users to perform high-qualit
- Alimera Sciences Appoints David Dyer, MD, as Chief Retina Specialisthttps://modernod.com/news/alimera-sciences-appoints-david-dyer-md-as-chief-retina-specialist/2479222/Alimera Sciences has announced the expansion of its leadership team with the appointment of David Dyer, MD, as chief retina specialist, effective today. Dr. Dyer brings his extensive medical knowledge and business exp
- Rayner Receives FDA Approval for RayOne Spheric Monofocal IOLhttps://modernod.com/news/rayner-receives-fda-approval-for-rayone-spheric-monofocal-iol/2479221/Rayner has received FDA approval for the RayOne Spheric fully-preloaded monofocal IOL. The approval marks Rayner’s third FDA approval in under 3 years within its RayOne preloaded IOL portfolio. RayOne Spheric joins RayOne Aspheric (FDA approved December 2018) and RayOne EMV, a new non-diffractive
- Three Companies Combine to Form Corza Medicalhttps://modernod.com/news/three-companies-combine-to-form-corza-medical/2479217/Corza Medical, a provider of surgical products and technologies, was formed after uniting Surgical Specialties Corporation, Caliber Ophthalmics, and the TachoSil hemostatic patch device. &
- Biogen’s Phase 2/3 Gene Therapy Study for XLRP Fails to Meet Primary Endpointhttps://modernod.com/news/biogens-phase-2-3-gene-therapy-study-for-xlrp-fails-to-meet-primary-endpoint/2479216/Biogen announced topline results from the phase 2/3 XIRIUS study of cotoretigene toliparvovec (BIIB112), a gene therapy being investigated as a one-time therapy for patients with X-linked retinitis pigmentosa (XLRP). The XIRIUS study did not meet its primary endpoint of demonstrating a st
- SIFI and Bausch Health Russia Announce Strategic Commercial Partnershiphttps://modernod.com/news/sifi-and-bausch-health-russia-announce-strategic-commercial-partnership/2479213/Italian ophthalmic company SIFI announced it has entered into a strategic multi-year agreement with Bausch Health Russia to market its products treating ophthalmic disorders in Russia. Terms of the deal were not disclosed. Initial sales are expected in 2021, marketing 5 SIFI product
- EyeTech Digital Systems Releases the EyeOn Open Eye-Tracking Platformhttps://modernod.com/news/eyetech-digital-systems-releases-the-eyeon-open-eye-tracking-platform/2479214/EyeTech Digital Systems announced the release of its software ecosystem for the EyeOn family of eye-tracking tablets. Software-agnostic EyeOn devices support EyeTech’s applications as well as third-party applications, arming engineers and end users with the highest reliability and lowest in
- At-Home App Helps Patients Stay Engaged and Adherent to Vision Monitoring Remotelyhttps://modernod.com/news/at-home-app-helps-patients-stay-engaged-and-adherent-to-vision-monitoring-remotely/2479208/Novartis announced it has begun a US pilot program for OdySight, a clinically tested mobile application designed to help monitor vision remotely. Recent changes to public health protocols, paired with a growing patient population and existing treatment burden, have placed an emphasis on vi